Department of Metabolic Health Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands.
VitalNext, Wageningen, the Netherlands.
Metabolism. 2019 Aug;97:57-67. doi: 10.1016/j.metabol.2019.05.012. Epub 2019 May 31.
Muscle atrophy is defined as decreased muscle mass, associated with aging as well as with various chronic diseases and is a fundamental cause of frailty, functional decline and disability. Frailty represents a huge potential public health issue worldwide with high impact on healthcare costs. A major clinical issue is therefore to devise new strategies preventing muscle atrophy. In this study, we tested the efficacy of Vital01, a novel oral nutritional supplement (ONS), on body weight and muscle mass using a caloric restriction-induced mouse model for muscle atrophy.
Mice were calorically restricted for 2 weeks to induce muscle atrophy: one control group received 60% kcal of the normal chow diet and one intervention group received 30% kcal chow and 30 kcal% Vital01. The effects on body weight, lean body mass, muscle histology and transcriptome were assessed. In addition, the effects of Vital01, in mice with established muscle atrophy, were assessed and compared to a standard ONS. To this end, mice were first calorically restricted on a 60% kcal chow diet and then refed with either 100 kcal% chow, a mix of Vital01 (receiving 60% kcal chow and 40 kcal% Vital01) or with a mix of standard, widely prescribed ONS (receiving 60 kcal% chow and 40 kcal% Fortisip Compact).
Vital01 attenuated weight loss (-15% weight loss for Vital01 vs. -25% for control group, p < 0.01) and loss of muscle mass (Vital01 with -13%, -12% and -18%, respectively, for gastrocnemius, quadriceps and tibialis vs. 25%, -23% and -28%, respectively, for control group, all p < 0.05) and also restored body weight, fat and muscle mass more efficiently when compared to Fortisip Compact. As assessed by transcriptome analysis and Western blotting of key proteins (e.g. phospoAKT, mTOR and S6K), Vital01 attenuated the catabolic and anabolic signaling pathways induced by caloric restriction and modulated inflammatory and mitochondrial pathways. In addition, Vital01 affected pathways related to matrix proteins/collagens homeostasis and tended to reduce caloric restriction-induced collagen fiber density in the quadriceps (with -27%, p = 0.051).
We demonstrate that Vital01 preserves muscle mass in a calorically restricted mouse model for muscle atrophy. Vital01 had preventive effects when administered during development of muscle atrophy. Furthermore, when administered in a therapeutic setting to mice with established muscle atrophy, Vital01 rapidly restored body weight and accelerated the recurrence of fat and lean body mass more efficiently than Fortisip Compact. Bioinformatics analysis of gene expression data identified regulatory pathways that were specifically influenced by Vital01 in muscle.
肌肉萎缩是指肌肉质量下降,与衰老以及各种慢性疾病有关,是虚弱、功能下降和残疾的根本原因。虚弱是一个全球性的重大潜在公共卫生问题,对医疗保健成本有重大影响。因此,一个主要的临床问题是制定新的策略来预防肌肉萎缩。在这项研究中,我们使用热量限制诱导的肌肉萎缩小鼠模型,测试了一种新型口服营养补充剂(ONS)Vital01 对体重和肌肉质量的功效。
将小鼠进行热量限制 2 周以诱导肌肉萎缩:一组对照鼠接受正常饲料的 60%热量,一组干预鼠接受 30%正常饲料和 30% Vital01。评估了体重、瘦体重、肌肉组织学和转录组的变化。此外,还评估了 Vital01 在已发生肌肉萎缩的小鼠中的功效,并与标准 ONS 进行了比较。为此,首先将小鼠进行热量限制(60%的正常饲料),然后再喂食 100%的饲料、Vital01 混合物(接受 60%的正常饲料和 40%的 Vital01)或标准、广泛使用的 ONS(接受 60%的正常饲料和 40%的 Fortisip Compact)。
Vital01 减轻了体重下降(Vital01 组体重下降 15%,对照组体重下降 25%,p<0.01)和肌肉质量损失(Vital01 组的腓肠肌、股四头肌和胫骨分别下降 13%、12%和 18%,对照组分别下降 25%、23%和 28%,均 p<0.05),并且与 Fortisip Compact 相比,体重、脂肪和肌肉质量的恢复效率更高。通过关键蛋白的转录组分析和 Western blot 分析(如磷酸 AKT、mTOR 和 S6K),Vital01 减轻了热量限制诱导的分解代谢和合成代谢信号通路,并调节了炎症和线粒体途径。此外,Vital01 还影响与基质蛋白/胶原稳态相关的途径,并倾向于降低热量限制引起的股四头肌中胶原纤维密度(下降 27%,p=0.051)。
我们证明 Vital01 可维持肌肉萎缩的热量限制小鼠模型中的肌肉质量。Vital01 在肌肉萎缩发生时具有预防作用。此外,当 Vital01 在已发生肌肉萎缩的小鼠中进行治疗性给药时,它能更有效地快速恢复体重,并加速脂肪和瘦体重的恢复。基因表达数据的生物信息学分析确定了 Vital01 特异性影响肌肉的调节途径。